JP2020524698A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020524698A5 JP2020524698A5 JP2019571038A JP2019571038A JP2020524698A5 JP 2020524698 A5 JP2020524698 A5 JP 2020524698A5 JP 2019571038 A JP2019571038 A JP 2019571038A JP 2019571038 A JP2019571038 A JP 2019571038A JP 2020524698 A5 JP2020524698 A5 JP 2020524698A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- canakinumab
- use according
- functional fragment
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000012634 fragment Substances 0.000 claims description 54
- 229960001838 canakinumab Drugs 0.000 claims description 51
- 229940127089 cytotoxic agent Drugs 0.000 claims description 37
- 239000002246 antineoplastic agent Substances 0.000 claims description 35
- 239000003814 drug Substances 0.000 claims description 32
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 31
- 229940124597 therapeutic agent Drugs 0.000 claims description 31
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 29
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 29
- 206010061218 Inflammation Diseases 0.000 claims description 26
- 230000004054 inflammatory process Effects 0.000 claims description 26
- 208000020816 lung neoplasm Diseases 0.000 claims description 25
- 206010028980 Neoplasm Diseases 0.000 claims description 23
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 22
- 201000005202 lung cancer Diseases 0.000 claims description 22
- 201000011510 cancer Diseases 0.000 claims description 18
- 102100032752 C-reactive protein Human genes 0.000 claims description 15
- 230000002265 prevention Effects 0.000 claims description 14
- 229960003301 nivolumab Drugs 0.000 claims description 9
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 7
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 7
- 102000004889 Interleukin-6 Human genes 0.000 claims description 6
- 108090001005 Interleukin-6 Proteins 0.000 claims description 6
- 239000012271 PD-L1 inhibitor Substances 0.000 claims description 6
- 229940100601 interleukin-6 Drugs 0.000 claims description 6
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims description 6
- 229960002621 pembrolizumab Drugs 0.000 claims description 6
- 229960003852 atezolizumab Drugs 0.000 claims description 5
- 229950002916 avelumab Drugs 0.000 claims description 5
- 229950009791 durvalumab Drugs 0.000 claims description 5
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 4
- 238000011518 platinum-based chemotherapy Methods 0.000 claims description 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
- 229960003668 docetaxel Drugs 0.000 claims description 2
- 229910052697 platinum Inorganic materials 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 55
- 239000012270 PD-1 inhibitor Substances 0.000 claims 2
- 239000012668 PD-1-inhibitor Substances 0.000 claims 2
- 229940121655 pd-1 inhibitor Drugs 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229940071643 prefilled syringe Drugs 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 12
- 208000006265 Renal cell carcinoma Diseases 0.000 description 11
- 206010009944 Colon cancer Diseases 0.000 description 6
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 description 6
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 6
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 6
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 206010005003 Bladder cancer Diseases 0.000 description 3
- 208000034578 Multiple myelomas Diseases 0.000 description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 3
- 229960000397 bevacizumab Drugs 0.000 description 3
- 201000004101 esophageal cancer Diseases 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 229960005386 ipilimumab Drugs 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 201000005112 urinary bladder cancer Diseases 0.000 description 3
- YXTKHLHCVFUPPT-YYFJYKOTSA-N (2s)-2-[[4-[(2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid;(1r,2r)-1,2-dimethanidylcyclohexane;5-fluoro-1h-pyrimidine-2,4-dione;oxalic acid;platinum(2+) Chemical compound [Pt+2].OC(=O)C(O)=O.[CH2-][C@@H]1CCCC[C@H]1[CH2-].FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 YXTKHLHCVFUPPT-YYFJYKOTSA-N 0.000 description 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 229940123237 Taxane Drugs 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- JYEFSHLLTQIXIO-SMNQTINBSA-N folfiri regimen Chemical compound FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 JYEFSHLLTQIXIO-SMNQTINBSA-N 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 229960002633 ramucirumab Drugs 0.000 description 2
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 239000002525 vasculotropin inhibitor Substances 0.000 description 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 description 1
- 229940121849 Mitotic inhibitor Drugs 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 108010081667 aflibercept Proteins 0.000 description 1
- 201000009036 biliary tract cancer Diseases 0.000 description 1
- 208000020790 biliary tract neoplasm Diseases 0.000 description 1
- 229960001292 cabozantinib Drugs 0.000 description 1
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 201000002120 neuroendocrine carcinoma Diseases 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 229960002760 ziv-aflibercept Drugs 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023014125A JP2023071657A (ja) | 2017-06-22 | 2023-02-01 | がんの処置における使用のためのＩＬ－１β結合性抗体 |
Applications Claiming Priority (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762523458P | 2017-06-22 | 2017-06-22 | |
| US62/523,458 | 2017-06-22 | ||
| US201762529515P | 2017-07-07 | 2017-07-07 | |
| US62/529,515 | 2017-07-07 | ||
| US201762550325P | 2017-08-25 | 2017-08-25 | |
| US201762550307P | 2017-08-25 | 2017-08-25 | |
| US62/550,325 | 2017-08-25 | ||
| US62/550,307 | 2017-08-25 | ||
| US201762596054P | 2017-12-07 | 2017-12-07 | |
| US62/596,054 | 2017-12-07 | ||
| US201862649631P | 2018-03-29 | 2018-03-29 | |
| US62/649,631 | 2018-03-29 | ||
| PCT/IB2018/053096 WO2018234879A1 (en) | 2017-06-22 | 2018-05-03 | Il-1beta binding antibodies for use in treating cancer |
| TW107115136A TW201904993A (zh) | 2017-06-22 | 2018-05-03 | IL-1β 結合抗體之用途 |
| US15/970,542 | 2018-05-03 | ||
| IBPCT/IB2018/053096 | 2018-05-03 | ||
| US15/970,542 US20190048072A1 (en) | 2017-06-22 | 2018-05-03 | USE OF IL-1beta BINDING ANTIBODIES |
| TW107115136 | 2018-05-03 | ||
| PCT/IB2018/054637 WO2018235056A1 (en) | 2017-06-22 | 2018-06-22 | Il-1beta binding antibodies for use in treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023014125A Division JP2023071657A (ja) | 2017-06-22 | 2023-02-01 | がんの処置における使用のためのＩＬ－１β結合性抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020524698A JP2020524698A (ja) | 2020-08-20 |
| JP2020524698A5 true JP2020524698A5 (OSRAM) | 2021-08-05 |
Family
ID=62530267
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019570897A Withdrawn JP2020524694A (ja) | 2017-06-22 | 2018-05-03 | がんの処置における使用のためのＩＬ−１β結合性抗体 |
| JP2019571038A Withdrawn JP2020524698A (ja) | 2017-06-22 | 2018-06-22 | がんの処置における使用のためのＩＬ−１β結合性抗体 |
| JP2022146790A Pending JP2022181214A (ja) | 2017-06-22 | 2022-09-15 | がんの処置における使用のためのＩＬ－１β結合性抗体 |
| JP2023014125A Withdrawn JP2023071657A (ja) | 2017-06-22 | 2023-02-01 | がんの処置における使用のためのＩＬ－１β結合性抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019570897A Withdrawn JP2020524694A (ja) | 2017-06-22 | 2018-05-03 | がんの処置における使用のためのＩＬ−１β結合性抗体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022146790A Pending JP2022181214A (ja) | 2017-06-22 | 2022-09-15 | がんの処置における使用のためのＩＬ－１β結合性抗体 |
| JP2023014125A Withdrawn JP2023071657A (ja) | 2017-06-22 | 2023-02-01 | がんの処置における使用のためのＩＬ－１β結合性抗体 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20190048072A1 (OSRAM) |
| EP (1) | EP3642234A1 (OSRAM) |
| JP (4) | JP2020524694A (OSRAM) |
| KR (2) | KR20200019865A (OSRAM) |
| CN (1) | CN110831967A (OSRAM) |
| AU (4) | AU2018287519B2 (OSRAM) |
| BR (1) | BR112019027558A2 (OSRAM) |
| CA (2) | CA3061874A1 (OSRAM) |
| CL (1) | CL2019003799A1 (OSRAM) |
| CO (1) | CO2019014433A2 (OSRAM) |
| IL (1) | IL271221A (OSRAM) |
| JO (1) | JOP20190292A1 (OSRAM) |
| MX (1) | MX2019015516A (OSRAM) |
| PH (1) | PH12019502857A1 (OSRAM) |
| RU (1) | RU2020102237A (OSRAM) |
| SG (1) | SG11201911283UA (OSRAM) |
| TW (3) | TW201904993A (OSRAM) |
| WO (1) | WO2018234879A1 (OSRAM) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013122544A2 (en) | 2012-02-13 | 2013-08-22 | Agency For Science, Technology And Research | IL-1β NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES |
| WO2018234879A1 (en) * | 2017-06-22 | 2018-12-27 | Novartis Ag | Il-1beta binding antibodies for use in treating cancer |
| CN112584857A (zh) * | 2018-05-09 | 2021-03-30 | 诺华股份有限公司 | 卡那吉努单抗的用途 |
| KR20210108422A (ko) * | 2018-12-21 | 2021-09-02 | 노파르티스 아게 | IL-1β 결합 항체의 용도 |
| US11718673B2 (en) * | 2019-04-01 | 2023-08-08 | Immetas Therapeutics, Inc. | Bispecific binding molecules that target the tumor microenvironment and an immune checkpoint protein |
| CA3142662A1 (en) * | 2019-06-06 | 2020-12-10 | Sitokine Limited | Compositions and methods for treating lung, colorectal and breast cancer |
| CN114423792A (zh) * | 2019-07-09 | 2022-04-29 | 拓维创新生物科技(香港)有限公司 | 针对TNF-α和IL-1β的双特异性抗体及其用途 |
| KR20220152318A (ko) * | 2020-03-12 | 2022-11-15 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
| RU2745814C1 (ru) * | 2020-06-05 | 2021-04-01 | Закрытое Акционерное Общество "Биокад" | Водная фармацевтическая композиция левилимаба и ее применение |
| EP3970727A1 (en) * | 2020-09-16 | 2022-03-23 | Johann Wolfgang Goethe-Universität Frankfurt | Means for reducing radiotherapy resistance and adverse effects |
| WO2022091375A1 (ja) * | 2020-10-30 | 2022-05-05 | 国立研究開発法人国立循環器病研究センター | 周産期心筋症治療剤 |
| WO2022167916A1 (en) * | 2021-02-03 | 2022-08-11 | Novartis Ag | Use of il-1b binding antibodies for treating neuroinflammatory disorders |
| WO2023038619A1 (en) * | 2021-09-08 | 2023-03-16 | Board Of Regents, The University Of Texas System | USE OF IL-1β BINDING ANTIBODIES |
| CN115125303B (zh) * | 2022-06-07 | 2023-02-24 | 北京大学第一医院 | 阿帕替尼药敏标记物及其相关试剂的应用 |
| CN116139268A (zh) * | 2023-03-13 | 2023-05-23 | 上海交通大学医学院附属仁济医院 | 靶向IL-1β的抗体在制备治疗去势抵抗型前列腺癌中的用途 |
| CN116688130A (zh) * | 2023-06-08 | 2023-09-05 | 桂林医学院附属医院 | 靶向IL-1β/IL-1R1通路的拮抗剂在抑制肝癌肺转移前微环境或肺转移的药物中的应用 |
| WO2024258943A1 (en) * | 2023-06-13 | 2024-12-19 | Merck Sharp & Dohme Llc | Methods of using cyclic peptides for trapping interleukin-1 beta |
| WO2025235276A1 (en) * | 2024-05-06 | 2025-11-13 | Icahn School Of Medicine At Mount Sinai | Combination of il-1 receptor inhibitors, anti pd-1, and il-4 inhibitors in the treatment of cancer |
| WO2025242806A1 (en) | 2024-05-23 | 2025-11-27 | Universität Duisburg-Essen | A METHOD FOR PREDICTING THE RESPONSE OF A PATIENT WITH DLBCL TO ANTI-IL-1ß THERAPY |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1234031T (pt) | 1999-11-30 | 2017-06-26 | Mayo Foundation | B7-h1, uma nova molécula imunoregulatória |
| GB0020685D0 (en) | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| EP1537878B1 (en) | 2002-07-03 | 2010-09-22 | Ono Pharmaceutical Co., Ltd. | Immunopotentiating compositions |
| WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
| EP1866339B8 (en) | 2005-03-25 | 2021-12-01 | GITR, Inc. | Gitr binding molecules and uses therefor |
| PT1899378E (pt) | 2005-06-21 | 2010-01-26 | Xoma Technology Ltd | Anticorpos de ligação de il-1β e os seus fragmentos |
| KR101607288B1 (ko) | 2005-07-01 | 2016-04-05 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| TWI424147B (zh) | 2005-07-04 | 2014-01-21 | 尼康美景股份有限公司 | Distance measuring device |
| US9303080B2 (en) | 2006-01-13 | 2016-04-05 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health | Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells |
| PL2374818T3 (pl) | 2006-06-02 | 2013-05-31 | Regeneron Pharma | Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6 |
| US9244059B2 (en) | 2007-04-30 | 2016-01-26 | Immutep Parc Club Orsay | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| EP2160401B1 (en) | 2007-05-11 | 2014-09-24 | Altor BioScience Corporation | Fusion molecules and il-15 variants |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| US20090258020A1 (en) * | 2008-01-07 | 2009-10-15 | Patrys Limited | Antibody designated barb3, barb3 related antibodies, and methods of making and using same |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| US20110159023A1 (en) | 2008-08-25 | 2011-06-30 | Solomon Langermann | Pd-1 antagonists and methods for treating infectious disease |
| WO2010029435A1 (en) | 2008-09-12 | 2010-03-18 | Isis Innovation Limited | Pd-1 specific antibodies and uses thereof |
| HUE030807T2 (en) | 2008-09-26 | 2017-05-29 | Dana Farber Cancer Inst Inc | Human anti-PD-1, anti-PD-L1 and anti-PD-L2 antibodies and their applications |
| TWI729512B (zh) | 2008-12-09 | 2021-06-01 | 美商建南德克公司 | 抗pd-l1抗體及其於增進t細胞功能之用途 |
| EP2196476A1 (en) * | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
| CN102574924A (zh) | 2009-09-03 | 2012-07-11 | 先灵公司 | 抗-gitr抗体 |
| CN104961829B (zh) | 2009-11-24 | 2018-08-21 | 米迪缪尼有限公司 | 针对b7-h1的靶向结合剂 |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| CN102892786B (zh) | 2010-03-11 | 2016-03-16 | Ucb医药有限公司 | Pd-1抗体 |
| CN103079644B (zh) | 2010-06-11 | 2017-02-15 | 协和发酵麒麟株式会社 | 抗tim‑3抗体 |
| JP2013532153A (ja) | 2010-06-18 | 2013-08-15 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体 |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| RU2013144392A (ru) | 2011-03-03 | 2015-04-10 | Апексиджен, Инк. | Антитела к рецептору il-6 и способы применения |
| WO2012121679A1 (en) * | 2011-03-09 | 2012-09-13 | Agency For Science, Technology And Research | Method of modulating phenotype of a renal cell cancer-associated monocyte or macrophage |
| DK2699264T3 (en) | 2011-04-20 | 2018-06-25 | Medimmune Llc | ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1 |
| EP2537933A1 (en) | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | An IL-15 and IL-15Ralpha sushi domain based immunocytokines |
| WO2013006490A2 (en) | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
| KR101981873B1 (ko) | 2011-11-28 | 2019-05-23 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| WO2013122544A2 (en) * | 2012-02-13 | 2013-08-22 | Agency For Science, Technology And Research | IL-1β NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES |
| KR102410078B1 (ko) | 2012-05-31 | 2022-06-22 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Pd-l1에 결합하는 항원 결합 단백질 |
| JO3300B1 (ar) | 2012-06-06 | 2018-09-16 | Novartis Ag | مركبات وتركيبات لتعديل نشاط egfr |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| EP2890715B1 (en) | 2012-08-03 | 2020-12-16 | Dana-Farber Cancer Institute, Inc. | Single agent anti-pd-l1 and pd-l2 dual binding antibodies and methods of use |
| WO2014055897A2 (en) | 2012-10-04 | 2014-04-10 | Dana-Farber Cancer Institute, Inc. | Human monoclonal anti-pd-l1 antibodies and methods of use |
| NZ630790A (en) | 2012-10-24 | 2016-11-25 | Admune Therapeutics Llc | Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes |
| AR093984A1 (es) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
| MY210104A (en) | 2013-03-15 | 2025-08-27 | Glaxosmithkline Ip Dev Ltd | Anti-lag-3 binding proteins |
| PT2992017T (pt) | 2013-05-02 | 2021-01-29 | Anaptysbio Inc | Anticorpos dirigidos contra a morte programada 1 (pd-1) |
| HK1221964A1 (zh) | 2013-05-31 | 2017-06-16 | Sorrento Therapeutics, Inc. | 与pd-1结合的抗原结合蛋白 |
| US20160145355A1 (en) | 2013-06-24 | 2016-05-26 | Biomed Valley Discoveries, Inc. | Bispecific antibodies |
| AR097306A1 (es) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
| TW201605896A (zh) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | Gitr抗原結合蛋白 |
| RS63571B9 (sr) | 2013-09-13 | 2023-02-28 | Beigene Switzerland Gmbh | Anti-pd1 antitela i njihova primena kao terapeutska i dijagnostička sredstva |
| AU2014339900B2 (en) | 2013-10-25 | 2019-10-24 | Dana-Farber Cancer Institute, Inc. | Anti-PD-L1 monoclonal antibodies and fragments thereof |
| WO2015081158A1 (en) | 2013-11-26 | 2015-06-04 | Bristol-Myers Squibb Company | Method of treating hiv by disrupting pd-1/pd-l1 signaling |
| WO2015083120A1 (en) * | 2013-12-04 | 2015-06-11 | Novartis Ag | USE OF IL-1β BINDING ANTIBODIES |
| PL3081576T3 (pl) | 2013-12-12 | 2020-03-31 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Przeciwciało anty pd-1, jego fragment wiążący antygen i ich zastosowanie medyczne |
| HUE057917T2 (hu) | 2014-01-15 | 2022-06-28 | Kadmon Corp Llc | Immunmodulátor szerek |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| PT3556775T (pt) | 2014-01-28 | 2021-12-31 | Bristol Myers Squibb Co | Anticorpos anti-lag-3 para tratar neoplasias malignas hematológicas |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| EP3660050A1 (en) | 2014-03-14 | 2020-06-03 | Novartis AG | Antibody molecules to lag-3 and uses thereof |
| TW202132337A (zh) | 2014-05-28 | 2021-09-01 | 美商艾吉納斯公司 | 抗糖皮質素誘導性ｔｎｆｒ家族相關性受體（ｇｉｔｒ）抗體類及使用彼等之方法 |
| EP3149042B1 (en) | 2014-05-29 | 2019-08-28 | Spring Bioscience Corporation | Pd-l1 antibodies and uses thereof |
| AU2015271709B2 (en) | 2014-06-06 | 2020-11-26 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof |
| WO2015195163A1 (en) | 2014-06-20 | 2015-12-23 | R-Pharm Overseas, Inc. | Pd-l1 antagonist fully human antibody |
| TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| US10544225B2 (en) | 2014-07-03 | 2020-01-28 | Beigene, Ltd. | Anti-PD-L1 antibodies and their use as therapeutics and diagnostics |
| JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| CA2962976A1 (en) | 2014-10-03 | 2016-04-07 | Dana-Farber Cancer Institute, Inc. | Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| CN114920840A (zh) | 2014-10-14 | 2022-08-19 | 诺华股份有限公司 | 针对pd-l1的抗体分子及其用途 |
| EP3215532B1 (en) | 2014-11-06 | 2019-10-23 | F.Hoffmann-La Roche Ag | Anti-tim3 antibodies and methods of use |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| US20160200815A1 (en) | 2015-01-05 | 2016-07-14 | Jounce Therapeutics, Inc. | Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof |
| JP2018510151A (ja) | 2015-03-06 | 2018-04-12 | ソレント・セラピューティクス・インコーポレイテッド | Ｔｉｍ３に結合する抗体医薬 |
| IL283006B2 (en) | 2015-04-01 | 2023-10-01 | Anaptysbio Inc | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) |
| EP3294301A4 (en) * | 2015-05-12 | 2019-01-09 | Drexel University | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF CANCER METASTAS AND METHODS THEREWITH |
| CA2988115A1 (en) | 2015-06-03 | 2016-12-08 | Bristol-Myers Squibb Company | Anti-gitr antibodies for cancer diagnostics |
| RU2753439C2 (ru) | 2015-07-23 | 2021-08-16 | Инхибркс, Инк. | Поливалетные и полиспецифичные gitr-связывающие слитые белки |
| US20180222982A1 (en) * | 2015-07-29 | 2018-08-09 | Novartis Ag | Combination therapies comprising antibody molecules to pd-1 |
| KR20180033588A (ko) | 2015-08-12 | 2018-04-03 | 메디뮨 리미티드 | Ｇｉｔｒｌ 융합 단백질 및 그의 용도 |
| WO2018234879A1 (en) * | 2017-06-22 | 2018-12-27 | Novartis Ag | Il-1beta binding antibodies for use in treating cancer |
-
2018
- 2018-05-03 WO PCT/IB2018/053096 patent/WO2018234879A1/en not_active Ceased
- 2018-05-03 US US15/970,542 patent/US20190048072A1/en not_active Abandoned
- 2018-05-03 JP JP2019570897A patent/JP2020524694A/ja not_active Withdrawn
- 2018-05-03 AU AU2018287519A patent/AU2018287519B2/en not_active Ceased
- 2018-05-03 KR KR1020197035726A patent/KR20200019865A/ko not_active Ceased
- 2018-05-03 TW TW107115136A patent/TW201904993A/zh unknown
- 2018-05-03 CA CA3061874A patent/CA3061874A1/en active Pending
- 2018-06-22 BR BR112019027558-4A patent/BR112019027558A2/pt not_active Application Discontinuation
- 2018-06-22 CN CN201880041546.8A patent/CN110831967A/zh active Pending
- 2018-06-22 MX MX2019015516A patent/MX2019015516A/es unknown
- 2018-06-22 US US16/624,130 patent/US20230220063A1/en not_active Abandoned
- 2018-06-22 TW TW112108903A patent/TW202400641A/zh unknown
- 2018-06-22 TW TW107121619A patent/TW201904995A/zh unknown
- 2018-06-22 RU RU2020102237A patent/RU2020102237A/ru unknown
- 2018-06-22 JP JP2019571038A patent/JP2020524698A/ja not_active Withdrawn
- 2018-06-22 AU AU2018288060A patent/AU2018288060B2/en not_active Ceased
- 2018-06-22 SG SG11201911283UA patent/SG11201911283UA/en unknown
- 2018-06-22 CA CA3066045A patent/CA3066045A1/en active Pending
- 2018-06-22 KR KR1020207001676A patent/KR20200021086A/ko not_active Ceased
- 2018-06-22 EP EP18749503.1A patent/EP3642234A1/en not_active Withdrawn
- 2018-06-22 PH PH1/2019/502857A patent/PH12019502857A1/en unknown
- 2018-12-22 JO JOP/2019/0292A patent/JOP20190292A1/ar unknown
-
2019
- 2019-12-05 IL IL271221A patent/IL271221A/en unknown
- 2019-12-19 CO CONC2019/0014433A patent/CO2019014433A2/es unknown
- 2019-12-20 CL CL2019003799A patent/CL2019003799A1/es unknown
-
2021
- 2021-10-07 AU AU2021245184A patent/AU2021245184A1/en not_active Abandoned
- 2021-10-19 AU AU2021254559A patent/AU2021254559A1/en not_active Abandoned
-
2022
- 2022-01-10 US US17/572,228 patent/US20220389090A1/en not_active Abandoned
- 2022-09-15 JP JP2022146790A patent/JP2022181214A/ja active Pending
-
2023
- 2023-02-01 JP JP2023014125A patent/JP2023071657A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020524698A5 (OSRAM) | ||
| JP2020524694A5 (OSRAM) | ||
| EP2127652B1 (en) | Method for treating cancer using anticancer agent in combination | |
| Li et al. | Molecular‐targeted agents combination therapy for cancer: developments and potentials | |
| Bagatell et al. | Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study | |
| CA2926771C (en) | Cancer treatment with combination of plinabulin and taxane | |
| RU2020102237A (ru) | Связывающие il-1-бета антитела для применения в лечении рака | |
| Kanda et al. | Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy | |
| WO2019197605A2 (en) | Drug combinations for use in the treatment of ras-mutant cancer | |
| TW201141473A (en) | Combination therapy for small cell lung cancer | |
| CN105283178A (zh) | 用于治疗癌症的包含mps-1激酶抑制剂和有丝分裂抑制剂的组合 | |
| EP4196116B1 (en) | Pharmaceutical composition comprising cabozantinib, plerixafor, afatinib and etoricoxib for use in the treatment or prophylaxis of nsclc without driver mutations | |
| US12226454B2 (en) | Pharmaceutical compositions and use thereof for relieving anticancer drug resistance and enhancing sensitivity of anticancer drug | |
| EP4475847A1 (en) | An igf1r inhibitor and an akt inhibitor for use in the treatment of cancer | |
| Turkington et al. | A phase I trial of bortezomib in combination with epirubicin, carboplatin and capecitabine (ECarboX) in advanced oesophagogastric adenocarcinoma | |
| JPWO2020201138A5 (OSRAM) | ||
| Brown et al. | Novel approaches in the treatment of thyroid cancer | |
| Carter et al. | A prospective clinical trial of lenalidomide with topotecan in women with advanced epithelial ovarian carcinoma | |
| WO2024231875A1 (en) | Hpk1 inhibitor for use in the treatment of cancer | |
| Wibmer et al. | Efficacy and safety of combination chemotherapy with mitomycin and vinorelbine for the treatment of advanced non-small cell lung cancer | |
| US10507208B2 (en) | Compositions, packaged pharmaceuticals, and methods of using hedgehog pathway modulators for the sensitization of resistant tumors | |
| CA2530311A1 (en) | Cancer treatment with epothilones | |
| Goldenberg | Chemotherapy Foundation Symposium XXVI: Innovative Cancer Therapy for Tomorrow | |
| HK1229712B (en) | Cancer treatment with combination of plinabulin and taxane |